BRIEF-Allergan resumes trading down 11.5 percent after company says phase 2 eye drug data does not support directly moving to phase 3

NEW YORK Wed May 1, 2013 11:16am EDT

NEW YORK May 1 (Reuters) - Allergan Inc : * Resumes trading down 11.5 percent after company says phase 2 Darpin eye drug data does not support directly moving to phase 3

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.